A
Price
$115.80
Change
+$1.86 (+1.63%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
42.66B
74 days until earnings call
BLFS
Price
$23.73
Change
+$2.23 (+10.37%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
810.87M
62 days until earnings call
Interact to see
Advertisement

A vs BLFS

Header iconA vs BLFS Comparison
Open Charts A vs BLFSBanner chart's image
Agilent Technologies
Price$115.80
Change+$1.86 (+1.63%)
Volume$10.56K
Capitalization42.66B
BioLife Solutions
Price$23.73
Change+$2.23 (+10.37%)
Volume$9.02K
Capitalization810.87M
A vs BLFS Comparison Chart
Loading...
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BLFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
A vs. BLFS commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and BLFS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (A: $113.94 vs. BLFS: $21.50)
Brand notoriety: A and BLFS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: A: 78% vs. BLFS: 67%
Market capitalization -- A: $42.66B vs. BLFS: $810.87M
A [@Medical Specialties] is valued at $42.66B. BLFS’s [@Medical Specialties] market capitalization is $810.87M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

A’s FA Score shows that 1 FA rating(s) are green whileBLFS’s FA Score has 1 green FA rating(s).

  • A’s FA Score: 1 green, 4 red.
  • BLFS’s FA Score: 1 green, 4 red.
According to our system of comparison, A is a better buy in the long-term than BLFS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

A’s TA Score shows that 6 TA indicator(s) are bullish while BLFS’s TA Score has 3 bullish TA indicator(s).

  • A’s TA Score: 6 bullish, 2 bearish.
  • BLFS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, A is a better buy in the short-term than BLFS.

Price Growth

A (@Medical Specialties) experienced а +0.58% price change this week, while BLFS (@Medical Specialties) price change was -3.67% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.10%. For the same industry, the average monthly price growth was +5.39%, and the average quarterly price growth was +1.86%.

Reported Earning Dates

A is expected to report earnings on Aug 19, 2025.

BLFS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Medical Specialties (+2.10% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
A($42.7B) has a higher market cap than BLFS($811M). BLFS has higher P/E ratio than A: BLFS (238.10) vs A (34.82). A YTD gains are higher at: -15.005 vs. BLFS (-17.180). A has higher annual earnings (EBITDA): 1.69B vs. BLFS (-45.24M). BLFS has less debt than A: BLFS (42.7M) vs A (2.56B). A has higher revenues than BLFS: A (6.74B) vs BLFS (143M).
ABLFSA / BLFS
Capitalization42.7B811M5,265%
EBITDA1.69B-45.24M-3,736%
Gain YTD-15.005-17.18087%
P/E Ratio34.82238.1015%
Revenue6.74B143M4,710%
Total CashN/A51.7M-
Total Debt2.56B42.7M5,984%
FUNDAMENTALS RATINGS
A vs BLFS: Fundamental Ratings
A
BLFS
OUTLOOK RATING
1..100
83
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
95
Overvalued
PROFIT vs RISK RATING
1..100
6385
SMR RATING
1..100
4490
PRICE GROWTH RATING
1..100
6063
P/E GROWTH RATING
1..100
6713
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

A's Valuation (19) in the Biotechnology industry is significantly better than the same rating for BLFS (95) in the Medical Specialties industry. This means that A’s stock grew significantly faster than BLFS’s over the last 12 months.

A's Profit vs Risk Rating (63) in the Biotechnology industry is in the same range as BLFS (85) in the Medical Specialties industry. This means that A’s stock grew similarly to BLFS’s over the last 12 months.

A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for BLFS (90) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than BLFS’s over the last 12 months.

A's Price Growth Rating (60) in the Biotechnology industry is in the same range as BLFS (63) in the Medical Specialties industry. This means that A’s stock grew similarly to BLFS’s over the last 12 months.

BLFS's P/E Growth Rating (13) in the Medical Specialties industry is somewhat better than the same rating for A (67) in the Biotechnology industry. This means that BLFS’s stock grew somewhat faster than A’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABLFS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
61%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
61%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
50%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BLFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PGPCX25.55N/A
N/A
George Putnam Balanced C
THISX76.12N/A
N/A
T. Rowe Price Health Sciences I
SEQAX16.73N/A
N/A
NAA World Equity Income A
KCGSX21.23N/A
N/A
Knights of Columbus Large Cap Growth S
TCSHX14.64N/A
N/A
Transamerica Multi-Asset Income C

BLFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, BLFS has been loosely correlated with RGEN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BLFS jumps, then RGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLFS
1D Price
Change %
BLFS100%
-2.41%
RGEN - BLFS
55%
Loosely correlated
+0.17%
RVTY - BLFS
49%
Loosely correlated
-2.06%
A - BLFS
49%
Loosely correlated
-0.87%
DHR - BLFS
48%
Loosely correlated
-0.48%
TWST - BLFS
47%
Loosely correlated
-0.36%
More